Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy

Exclusion criteria

• . Any disabling, severe, or unstable medical or psychiatric condition that, in the opinion of the study physician, precludes safe participation in the study or the ability to provide fully informed consent, as assessed by medical and psychiatric history, physical examination, vital signs, and/or laboratory tests;
• . Any severe or unstable co-morbid substance use disorder (e.g., delirium tremens, acute alcohol intoxication) that, in the opinion of the study physician, precludes safe participation in the study;
• . Currently pregnant or breastfeeding, or planning to become pregnant;
• . Known or suspected allergy or hypersensitivity to cannabinoids;
• . History of respiratory disease, severe cardiovascular, cerebrovascular, renal or liver disease;
• . Current or historic cannabis use disorder;
• . Taking warfarin, clopidogrel, clobazam, theophylline, clozapine and olanzapine medications as they may interact with cannabinoids in a clinically significant manner if they cannot be switched to a different medication;
• . Any personal or family history (first degree relative) of primary psychotic disorders (i.e., schizophrenia, schizoaffective disorder) as per DSM-5 criteria;